Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study - Test2 - elhamkhani - TriplyDB

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

http://www.wikidata.org/entity/Q28314921

about

Current Landscape of Antiviral Drug Discovery Early-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease prevention Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Viral aetiology of bronchiolitis in hospitalised children in Qatar.Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children.How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts.Baicalin from Scutellaria baicalensis blocks respiratory syncytial virus (RSV) infection and reduces inflammatory cell infiltration and lung injury in mice.Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus (RSV) infected infants.Respiratory syncytial virus: prospects for new and emerging therapeutics.Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.Latest options for treatment of bronchiolitis in infants.Structure-guided design of small-molecule therapeutics against RSV disease.Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients.Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants.Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.Antiviral therapy for respiratory viral infections in immunocompromised patients.Respiratory Syncytial Virus Infection: An Illness for All Ages.Factors predicting life-threatening infections with respiratory syncytial virus in adult patients.Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children.Ongoing developments in RSV prophylaxis: a clinician's analysis.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.Real-life comparison of three general paediatric wards showed similar outcomes for children with bronchiolitis despite different treatment regimens.Powerful Diagnostic Methods Applied to a Unique Specimen Collection.The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, versus its achievable concentrations in the human respiratory tract and comparison to ribavirin.Oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus.Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.ENHANCING THE THERMOSTABILITY AND IMMUNOGENICITY OF AN RSV LIVE-ATTENUATED VACCINE BY INCORPORATING UNIQUE RSV LINE19F PROTEIN RESIDUES.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Adherence and outcomes: a systematic review of palivizumab utilization.A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time.Respiratory syncytial virus is an "opportunistic" killer.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Nucleosides for the treatment of respiratory RNA virus infections.Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium.

P2860

Q26766639-31902B91-5FC6-4035-81E0-36464C1EE970 Q28076551-BFCFDB82-649C-4AA7-9AF4-08FD2E46404C Q28548547-1FE27696-1FC1-4638-BC23-0343CBED3D98 Q28551925-8D100E14-C356-4CCB-B399-C821ACF723DC Q30240274-208CC213-4DF8-42C2-8A29-0C489B16B552 Q36279043-CCAECFBE-DD28-4114-80BE-A08DDB61CFB3 Q36748198-C2832010-D3DE-4221-BC11-B321B1E25E7C Q36965855-A7DA6B77-FDC3-4BD4-8969-07FE1975CB86 Q37049972-34E0F3C0-A1D2-408E-8A6D-A2B1FB3FFD29 Q37355470-433FBCCF-1925-475B-B85F-6A8B978AC4DD Q38650711-E570A00D-7AB9-44F1-B433-0F9FAC8E57D0 Q38671927-258A765B-7BE4-4FB3-BD49-DABD9930CB4B Q38675686-7C3276FB-4E16-433D-82B9-D1349058164B Q38742141-B9E44B67-454B-43FF-8169-93B74888993D Q38744226-3A42A518-EEF7-43BC-807A-77CA1F05872D Q38798541-58179BB5-B14E-47D0-8599-70718A376789 Q38829076-E76CCE2B-689B-4E07-9A6D-1B3524261906 Q38881879-804EB9C0-0B16-4F61-99E0-2A28B6043620 Q39038875-564E1D6F-CF69-4DB4-BAFD-7CCFD0979616 Q39076394-ADFD9687-0549-4FA2-9147-59CAF0678A7D Q39118423-0D727A6A-EA4E-4A6C-9E06-02FB9A4AFAF6 Q39136472-EBF4D436-C7DD-471C-AE42-BAE487919000 Q39294045-1B271807-E2AF-44CC-AF16-3662C1F87E3C Q39303791-2A7CD3E1-A29D-4CF1-9A28-EAF5BC409AAD Q39444008-7DD233C1-AD24-4363-A3F4-BAC90B169449 Q40144736-7343AF01-8A20-4A42-9E97-8EC6A5E9ED94 Q40199531-5EC9CD29-CFC9-42EF-91FF-BA12D7C5D08C Q40262456-B8A79AB7-5229-401D-B39E-FB0A7F470EE0 Q41921750-1D4CB552-6037-497C-8A49-8F2F1F77F4F7 Q41927841-77E9AD9F-BFC4-4103-90F7-A8172EC44259 Q45324676-6F0CF13D-E2C0-4B56-8FF1-38C52D4EB5EB Q47269161-619D97D0-AE94-45F2-AD89-86F84DE6088E Q47549703-10C9C733-E657-4A41-A5DE-40AE318926AF Q47582466-20951D3B-008B-48AA-A0F8-11D2A0AA986B Q48506169-886191DE-0419-4711-B3EB-6A456A880A59 Q49817370-CE0829F7-DA06-4E61-BBA7-536F75A14751 Q50262223-E69D25A7-5F3B-434B-84EC-3F8C2E11838D Q52644426-B84029B2-AA79-407C-9A4F-060B492CE7F8 Q54248394-C4DDBC7A-4ECD-40CF-B5C1-C782C0EAAE43 Q55400300-0EB09943-3353-4337-A63E-5720D36E12F5

P2860

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

http://www.wikidata.org/entity/Q28314921

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@ast

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@en

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@nl

type

label

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@ast

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@en

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@nl

prefLabel

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@ast

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@en

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@nl

P1433

Q28314921-BA678884-CD34-4353-A412-83CBF1C69548

P1476

Q28314921-5D7492A5-BBE8-412B-9636-65B84A9C009D

P2093

Q28314921-17365901-72FB-4D13-AF37-21E571845C81

Q28314921-23075D16-5D55-46B0-8A58-9817F4722286

Q28314921-2D83C39B-9340-4B14-ABB2-940D8A328542

Q28314921-421F08BE-071E-4EF1-8DFC-3D4D74DCF4BD

Q28314921-6057BDA7-48A0-487D-9FCB-E805BB646349

Q28314921-735FE728-106B-4C08-8134-BA9C987A378F

Q28314921-7F108340-C22D-41E4-9BF4-90F107D3765C

Q28314921-8E66BC2D-911B-4FF5-83E3-F7517BB35A62

Q28314921-8E9239CF-54B6-426A-9EEA-9F768F03B773

Q28314921-AFEC7A66-CB85-4095-8872-B1131CB7A566

P304

Q28314921-D7DBAD36-BEA0-478A-B79B-2780538D3832

P31

Q28314921-3F1735A7-567E-40B4-A0E1-650FD3836C39

P3181

Q28314921-E375A599-7746-472E-A438-51D3B7D71069

P356

Q28314921-7ACB1FF7-B8F0-4319-AC69-9160FF26E0EE

P407

Q28314921-26F76516-17D4-4F3B-9389-2DE1CB7935B0

P433

Q28314921-DA8A2737-58EF-4096-955C-5C64441B766D

P478

Q28314921-3066877C-46DD-45F4-AD07-85CBE46A733A

P50

Q28314921-06F8A179-0297-49F3-A0C6-D88320D3EBA1

P577

Q28314921-A971273B-14B7-429E-8C18-94E47D9014E3

P5875

Q28314921-8F92CF54-71F3-4614-B5A6-5E763227072F

P698

Q28314921-A0AE7E75-9FE9-4352-AC13-4B06635DE0E3

P921

Q28314921-AB6F1BC1-BE78-4551-B4C4-2555DA3F98CE

P3181

P356

P1433

The New England Journal of Medicine

P1476

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

@en

P2093

Christopher Westland

http://www.w3.org/2001/XMLSchema#string

Hosnieh Fathi

http://www.w3.org/2001/XMLSchema#string

John Fry

http://www.w3.org/2001/XMLSchema#string

John P. DeVincenzo

http://www.w3.org/2001/XMLSchema#string

Julian A. Symons

http://www.w3.org/2001/XMLSchema#string

Lawrence M. Blatt

http://www.w3.org/2001/XMLSchema#string

Leo Beigelman

http://www.w3.org/2001/XMLSchema#string

Matthew W. McClure

http://www.w3.org/2001/XMLSchema#string

Patrick Smith

http://www.w3.org/2001/XMLSchema#string

Qingling Zhang

http://www.w3.org/2001/XMLSchema#string

P304

2048-2058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

821355

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1413275

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Rob Lambkin-Williams

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284171205

http://www.w3.org/2001/XMLSchema#string

P698

26580997

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis